On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Risk of Transfusion-Transmitted Babesiosis” guidance document with a maximum 12 month implementation timeline. Per the FDA guidance document recommendations, CTS is developing a specific implementation plan for mandatory Babesia testing well before the May 8, 2020 deadline.
Check out the Communication page for the complete details by clicking the link: Communications
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
Reminder: On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the ch...
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...